Towards Multidrug Adaptive Therapy

Jeffrey West*, Li You, Jingsong Zhang, Robert A. Gatenby, Joel S. Brown, Paul K. Newton, Alexander R. A. Anderson*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    Abstract

    A new ecologically inspired paradigm in cancer treatment known as "adaptive therapy" capitalizes on competitive interactions between drug-sensitive and drug-resistant subclones. The goal of adaptive therapy is to maintain a controllable stable tumor burden by allowing a significant population of treatment-sensitive cells to survive. These, in turn, suppress proliferation of the less-fit resistant populations. However, there remain several open challenges in designing adaptive therapies, particularly in extending these therapeutic concepts to multiple treatments. We present a cancer treatment case study (metastatic castrate-resistant prostate cancer) as a point of departure to illustrate three novel concepts to aid the design of multidrug adaptive therapies. First, frequency-dependent "cycles" of tumor evolution can trap tumor evolution in a periodic, controllable loop. Second, the availability and selection of treatments may limit the evolutionary "absorbing region" reachable by the tumor. Third, the velocity of evolution significantly influences the optimal timing of drug sequences. These three conceptual advances provide a path forward for multidrug adaptive therapy.Significance: Driving tumor evolution into periodic, repeatable treatment cycles provides a path forward for multidrug adaptive therapy.
    Original languageEnglish
    Pages (from-to)1578-1589
    Number of pages12
    JournalCancer Research
    Volume80
    Issue number7
    DOIs
    Publication statusPublished - 1 Apr 2020

    Keywords

    • EVOLUTIONARY DYNAMICS
    • CLONAL EVOLUTION
    • SENSE EXCEPT
    • GLOBAL PLAN
    • CANCER
    • RESISTANCE
    • TUMORS
    • IMPLEMENTATION
    • HETEROGENEITY
    • STRATEGIES

    Fingerprint

    Dive into the research topics of 'Towards Multidrug Adaptive Therapy'. Together they form a unique fingerprint.

    Cite this